www.fdanews.com/articles/101106-schering-plough-s-pegintron-and-rebetol-combination-therapy-approved-in-eu
Schering-Plough's Pegintron and Rebetol Combination Therapy Approved in EU
November 15, 2007
Schering-Plough Corp. said the European Commission last month approved its 48-week standard-dose Pegintron and Rebetol combination therapy for chronic hepatitis C in adult patients whose prior treatment with interferon alpha and ribavirin combination therapy or interferon alpha monotherapy did not result in a sustained response.
Sharewatch
Sharewatch